ACM
TEVA icon

Advent Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Advent Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,700
Closed -$7K – 313
2017
Q3 		$7K Buy
+1,700
New +$38.3K ﹤0.01% 267
2017
Q2 		– Sell
-1,000
Closed -$11K – 322
2017
Q1 		$11K Buy
1,000
+850
+567% +$29K ﹤0.01% 245
2016
Q4 		$9K Buy
+150
New +$5.99K ﹤0.01% 270

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advent Capital Management's TEVA Position: Q4 2017 in Review

Advent Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 50,000 shares — an estimated $752K sold.

Advent Capital Management first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $880K in Q3 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Advent Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Advent Capital Management sold 50,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $752K.
  • Advent Capital Management first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Advent Capital Management's Teva Pharmaceuticals position peaked at $880K in Q3 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Advent Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.